Registration number: 11438683

Drug Discovery and Development Consultants Ltd

Annual Report and Unaudited Financial Statements for the Year Ended 31 May 2022

Tim Phillips & Co. Limited Cart House 2 Copley Hill Business Park Cambridge Road Babraham Cambridge CB22 3GN

Drug Discovery and Development Consultants Ltd

Contents

Company Information	-
Balance Sheet	=
Notes to the Financial Statements	2

Drug Discovery and Development Consultants Ltd

Company Information

Directors Mr Michael Higginbottom

Dr Stephen Anthony Burbidge Dr Martyn Clive Pritchard

Dr Maria Isabel Gonzalez Fernandez

Registered office Cart House 2

Copley Hill Business Park

Cambridge Road Babraham Cambridge CB22 3GN

Accountants Tim Phillips & Co. Limited

Cart House 2

Copley Hill Business Park

Cambridge Road Babraham Cambridge CB22 3GN

Drug Discovery and Development Consultants Ltd

(Registration number: 11438683) Balance Sheet as at 31 May 2022

	2022 £	2021 £
Current assets	72,033	70,333
Creditors: Amounts falling due within one year	(26,353)	(26,658)
Total assets less current liabilities	45,680	43,675
Accruals and deferred income	(945)	(870)
	44,735	42,805
Capital and reserves	44,735	42,805

1 Staff numbers

The average number of persons employed by the company (including directors) during the year, was 4 (2021 - 5).

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

For the financial year ending 31 May 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

Approved and authorised by the Board on 14 June 2022 and signed on its behalf by:

Mr Michael Higginbottom
Director

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.